Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript

Abbott Laboratories (NYSE: ABT ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more.

31, surpassing the midpoint of guidance and consensus estimates. 60. Significant pipeline achievements include FDA submission for Analyt360, CE mark for Libre Duo, and plans for several product launches over the next 12 months. 5%, despite an 8% decline in respiratory virus testing.

Nutrition sales outperformed expectations, driven by contract wins and new product innovations. 5%, with significant contributions from electrophysiology and rhythm management. Abbott plans to expand its continuous glucose monitoring business with a new manufacturing facility to meet anticipated demand. Management expressed confidence in maintaining growth momentum and executing on strategic priorities, citing strong pipeline and market dynamics.

Full Transcript OPERATOR Good morning and thank you for standing by. Welcome to Abbott Laboratories' second quarter 2026 earnings conference call. All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing the star 11 keys on your touchtone phone.

This call is being recorded by Abbott Laboratories with the exception of any participants' questions asked during the question and answer session. The entire call, including the question and answer session, is material copyrighted by Abbott Laboratories. It cannot be recorded or rebroadcast without Abbott Laboratories' expressed written permission. I would now like to introduce Mr.

Mike Camilla, Vice President, Investor Relations. Michael Comilla, Vice President, Investor Relations Good morning and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks following their comments.

We'll take your questions before we get started. Some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2026. Abbott Laboratories cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott Laboratories' operations are discussed in Item 1A Risk Factors to our Annual Report on Form 10K for the year ended December 31, 2025.

Abbott Laboratories undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law on today's conference call. As in the past, non-GAAP financial measures will be used to help investors understand Abbott Laboratories' ongoing business performance. com.

Note that Abbott Laboratories has not provided the related GAAP financial measures on a forward-looking basis for the non-GAAP financial measures for which it is providing guidance because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items which could significantly impact Abbott Laboratories' results in accordance with GAAP. Unless otherwise noted, our commentary on sales growth refers to comparable sales growth.

Our definition of comparable sales growth can be found on page two of our press release issued earlier today, and a reconciliation table containing the data needed to calculate comparable sales growth can be found on pages 16 and 17. With that, I will now turn the call over to Robert. Robert Ford, Chairman and Chief Executive Officer Okay, Mike. Good morning everyone and thank you for joining us.

31, which exceeded the midpoint of our guidance range and the consensus estimate. 60. Before summarizing our second quarter results, I want to highlight a few recent pipeline achievements including completing patient enrollments in our Tectonic Coronary IVL pivotal trial, completing our FDA submission for approval of our new Analyt360 left atrial appendage device, obtaining CE mark for Libre Duo, the world's first dual glucose ketone monitoring sensor designed to detect rising ketone levels and help prevent diabetic ketoacidosis.

We anticipate launching these three new products along with our Tactaflex Duo PFA catheter in the US in a steady cadence over the next 12 months. We also remain on track to begin patient enrollment in the fourth quarter for several important clinical trials that will support a steady cadence of future product launches and these include a balloon expandable TAVR valve, a leadless conduction system pacing device leveragi